The hollow fiber system model in the nonclinical evaluation of antituberculosis drug regimens

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S32-S33

  Chilukuri, Dakshina ^a   McMaster, Owen ^b   Bergman, Kimberly ^a   Colangelo, Philip ^a   Snow, Kerry ^b   Toerner, Joseph G ^b  

^a Laboratory of Molecular and Developmental Immunology Division of Monoclonal Antibodies Center for Drug Evaluation and Research   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antimycobacterial; In vitro; Tuberculosis

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PLASMA PROTEIN; RIFAMPICIN; TUBERCULOSTATIC AGENT; PYRAZINAMIDE;

ARTICLE; DRUG ACTIVITY; DRUG SCREENING; HOLLOW FIBER; HUMAN; KLEBSIELLA PNEUMONIAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLIC HEALTH; TUBERCULOSIS; ANTIBIOTIC THERAPY; SHORT SURVEY; BIOLOGICAL MODEL; COMBINATION DRUG THERAPY; DRUG EFFECTS;

ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84942156153     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ460     Document Type: Article

References (8)

1. World Health Organization. Global tuberculosis report 2013. Geneva, Switzerland: WHO, 2013. Available at: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf. Accessed 17 June 2015.
2. Centers for Disease Control and Prevention (CDC). Reported tuberculosis in the United States, 2012. Available at: http://www.cdc.gov/tb/statistics/reports/2012/pdf/report2012.pdf. Accessed 17 June 2015.
3. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Research Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-79.
4. Louie A, Vanscoy B, Liu W, Kulawy R, Drusano GL. Hollow-fiber pharmacodynamics studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children. Antimicrob Agents Chemother 2013; 57:5946-60.
5. Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors. Antimicrob Agents Chemother 2012; 56:2237-40.
6. Vanscoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother 2013; 57:4134-8.
7. Nightingale CH, Ambrose PG, Drusano GL, Murakawa T. Antimicrobial pharmacodynamics in theory and clinical practice. New York, NY: Informa Healthcare USA, 2007.
8. Vaddaday PK, Lee RE, Meibohm B. In vitro pharmacokinetic/pharmacodynamics models in anti-infective drug development: focus on TB. Future Med Chem 2010; 2:1355-69.